Quantitative Proteomic Analysis of Plasma Exosomes to Identify the Candidate Biomarker of Imatinib Resistance in Chronic Myeloid Leukemia Patients

BACKGROUND: Imatinib (IM), a tyrosine kinase inhibitor (TKI), has markedly improved the survival and life quality of chronic myeloid leukemia (CML) patients. However, the lack of specific biomarkers for IM resistance remains a serious clinical challenge. Recently, growing evidence has suggested that...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mei-Yong, Zhao, Cui, Chen, Lian, Yao, Fang-Yi, Zhong, Fang-Min, Chen, Ying, Xu, Shuai, Jiang, Jun-Yao, Yang, Yu-Lin, Min, Qing-Hua, Lin, Jin, Zhang, Hai-Bin, Liu, Jing, Wang, Xiao-Zhong, Huang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724304/
https://www.ncbi.nlm.nih.gov/pubmed/34993140
http://dx.doi.org/10.3389/fonc.2021.779567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724304/
https://www.ncbi.nlm.nih.gov/pubmed/34993140
http://dx.doi.org/10.3389/fonc.2021.779567

Ejemplares similares